Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Severe or Very Severe Alopecia Areata
CTR20192636Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in alopecia areata, sponsored by Eli Lilly and Company. Started Jan 2020; status: completed.
02
Drugs
baricitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on CTR20192636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192636.